PHOENIX, AZ--(Marketwired - August 26, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 to be held September 8-10, 2014 at the Grand Hyatt New York.
Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Tuesday, September 9, 2014 at 8:35 a.m. EDT.
To listen to the audio webcast of this presentation during the event, please visit: www.insysrx.com. A replay of this webcast will be available for 30 days after the initial presentation.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using its proprietary sublingual spray technology and its capability to develop pharmaceutical cannabinoids, the company addresses the clinical shortcomings of existing commercial products. The company currently markets two products, Subsys, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The company submitted a New Drug Application (NDA) to the FDA for an oral liquid formulation of Dronabinol in August 2014 and believes the oral solution formulation has distinct advantages over the current formulation of dronabinol in a soft gel capsule. The company is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.